Recursion Pharmaceuticals: High-Risk, High-Reward AI Platform in Drug Discovery with a Binary Outlook Hinged on Clinical Success
Overview
Recursion Pharmaceuticals operates as a clinical-stage 'TechBio' company with a unique platform-based approach to drug discovery, integrating high-throughput experiments, massive proprietary datasets, and advanced machine learning. Operating two parallel strategies, it develops an in-house drug pipeline—focused on oncology and rare diseases—and partners with major pharma for discovery programs, yielding substantial non-dilutive milestone revenues. Its business model is characterized by high R&D investment and a large cash position, sufficient to fund operations into 2027. The investment thesis revolves around the high-risk, high-reward potential that Recursion’s computational and experimental prowess can translate into successful drug approvals. Execution in the next two years is critical to this thesis.